GlobeNewsWire · CERO · October 26, 2026

CERo Therapeutics Announces Activation of Additional Clinical Trial Site for the CERTAIN-T Trial, its Ongoing Phase 1 Clinical Trial of CER-1236 in Hematological Cancers

Get the app for more

Explore stock news, insights and company research.